Anti‐proliferative and Pro‐apoptotic Properties of 3‐Bromoacetoxy Calcidiol in High‐risk Neuroblastoma
Authors:
- 5 October 2007
- journal article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 70 (4) , 302-310
Abstract
The cytotoxic, anti‐proliferative and apoptotic effects of 3‐Bromoacetoxy Calcidiol (B3CD), a derivative of vitamin D3 precursor calcidiol, on human neuroblastoma (NB) cells were examined. NB, predominantly a tumor of early childhood, is the most common extracranial solid tumor. Despite aggressive treatments, survival for advanced stages remains low and novel treatment strategies are needed. B3CD‐induced apoptosis in various neuroblastic cells via caspases‐3 and ‐9 activation. B3CD upregulated mitochondrial pro‐apoptotic Bax and anti‐apoptotic Bcl‐2 expression, caused cytochrome c release, downregulated N‐Myc expression and activated pro‐survival marker Akt. Accordingly, B3CD treatment dose dependently reduced the viability of NB cells with IC50 values between 1 and 3 μm. The cytotoxicity of B3CD was significantly higher than for the calcemic parent‐compound vitamin D3 (IC50 between 10 and 30 μm). Further studies revealed that B3CD treatment inhibits the proliferation of NB cells at low concentrations (IC50 between 30 and 100 nm). Cell cycle analysis showed a dramatic increase in the apoptotic sub‐diploidal population along with a cell cycle block. In summary, the present study shows that B3CD is toxic to NB cells via suppression of cell proliferation and cell viability by caspase activation and regulation of survival signals. These results suggest that B3CD could be developed as a treatment for NB.Keywords
This publication has 47 references indexed in Scilit:
- Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cellsBiochemical and Biophysical Research Communications, 2007
- Inhibition of Proliferation and Induction of Apoptosis by 25-Hydroxyvitamin D3-3β-(2)-Bromoacetate, a Nontoxic and Vitamin D Receptor-Alkylating Analog of 25-Hydroxyvitamin D3 in Prostate Cancer CellsClinical Cancer Research, 2004
- NeuroblastomaPediatric Drugs, 2004
- 1?,25-Dihydroxyvitamin D3-3?-(2)-bromoacetate, an affinity labeling derivative of 1?,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cellsJournal of Cellular Biochemistry, 2003
- 1α,25-Dihydroxyvitamin D3 – Not Just a Calciotropic HormoneNephron, 2002
- Intrinsic and extrinsic pathway signaling during neuronal apoptosisJournal of Cell Biology, 2002
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Measurement of vitamin D and its metabolites (calcidiol and calcitriol) and their clinical significanceScandinavian Journal of Clinical and Laboratory Investigation, 1997
- Measurement of vitamin D and its metabolites (calcidiol and calcitriol) and their clinical significanceScandinavian Journal of Clinical and Laboratory Investigation, 1997
- Affinity chromatography with 25-hydroxycholecalciferol ester in the isolation of the binding protein for vitamin D and its metabolites from human serumMetabolic Bone Disease and Related Research, 1981